MedTrace Logo

Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer

NCT00732082 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-06-12

No results posted yet for this study

Summary

The overall purpose of this research is to evaluate the safety and toxicity of an investigational medication, IMP321, in patients being treated with gemcitabine. IMP321 is a synthetic protein (made in the laboratory to simulate a protein that your body makes on its own) and was designed to stimulate the immune system with the overall objective of improving the body's capacity to react to your pancreas cancer.

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

Gemcitabine

BIOLOGICAL

LAG-3

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • William G. Hawkins, M.D. · Washington Univerisity

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-02-28
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00732082 on ClinicalTrials.gov